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Introduction
We present the case of a 51-years-old Caucasian woman with Bipolar Disorder I (BDI), treated for a long
time with typical antipsychotics and mood stabilizers. She referred to our outpatient service because she
wished to revise her precriptions, which had caused several side-effects, including metabolic syndrome,
gain of body weight, sedation, cognitive impairments, and extrapiramidal symptoms. Moreover, treatment
was poorly effective, the patient's compliance was lacking and she experienced frequent relapses.
Aims
We started treating the patient with aripiprazole at a daily dose of 15 mg. Our aim is to describe the
substantial clinical and metabolic improvements of a patient who poorly responded to previous
prescriptions.
Methods
Psychometric measures for the assessment of mood and social functioning were administered at baseline
and at the follow-up interviews. Body Mass Index was monitored and blood tests were performed to evaluate
the lipid profile (LDL, HDL, total cholesterol, triglycerides), blood glucose, and glycated haemoglobin.
Results
In the last two years the patient has regularly taken her therapies and attended to follow-up visits. Her social
functioning and tolerance to stressful situations have improved, as well as her metabolic profile. Noteworthy,
she had not needed further hospitalizations.
Conclusions
Our clinical observations support the efficacy of aripiprazole in the treatment of BDI. Switching to
aripiprazole should be considered in cases similar to the one we have described, characterized by poor
compliance, obesity or metabolic syndrome, sensitivity to manifest extrapiramidal syndrome (especially
tardive dyskinesia) and other side effects such as sedation and cognitive impairments.
